Neuroendocrine Tumors: all 682 studies
Page 1 of 7. Open to participants first (164), then studies with results posted, then the rest; newest registration first within each.
- A Phase 1 Study of IM-1340 in Participants With Advanced CancerNot yet recruitingNCT07890246Phase 1
- Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine NeoplasmsNot yet recruitingNCT07842172Phase 3
- Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid TumorsNot yet recruitingNCT07773454Phase 1
- Comparing DLL3 PET/CT to Standard Scans in Neuroendocrine CancerRecruitingNCT07733024Phase 2
- Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine NeoplasmsNot yet recruitingNCT07684170Phase 2
- 211At-MABG in Adults With Advanced Neuroendocrine CancersNot yet recruitingNCT07661420Phase 1
- A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine MalignanciesNot yet recruitingNCT07621146
- Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Cystic Neoplasms and Pancreatic Neuroendocrine TumorsRecruitingNCT07536087Not applicable
- Management of Pancreatic Cystic Lesions Using Artificial Intelligence Based on EUS and Multimodal DataRecruitingNCT07463872
- CardioNETPOL National Registry of Carcinoid Heart DiseaseNot yet recruitingNCT07450287
- Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocrine TumorsRecruitingNCT07404176Phase 2
- TheraSphere Japan Pre-Market StudyRecruitingNCT07377487Not applicable
- Sapu003 in Advanced mTOR-sensitive Solid TumorsRecruitingNCT07369505Phase 1
- Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor PatientsRecruitingNCT07366658Phase 1
- Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior TreatmentRecruitingNCT07314164
- Nutritional Status Assessment in Adult Patients Followed for Gastroenteropancreatic Neuroendocrine Tumors at Strasbourg University HospitalRecruitingNCT07302100
- Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine NeoplasmsRecruitingNCT07272512Phase 4
- Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a TumorAvailableNCT07262970
- Evaluation of Tolerance and Quality of Life in Patients With Neuroendocrine Tumors Treated With Oral Anti-Tumor Drugs Within a Therapeutic Education ProgramNot yet recruitingNCT07258810
- PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)RecruitingNCT07185672Phase 3
- Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.RecruitingNCT07165132Phase 1
- The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)RecruitingNCT07151391Phase 2
- An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine CancerRecruitingNCT07132645Early Phase 1
- Patients With High-grade Pancreatic Neuroendocrine TumorsEnrolling by invitationNCT07121478Phase 2
- 18F-AlF-NOTA-Octreotide PET in Neuroendocrine NeoplasmsNot yet recruitingNCT07102056
- Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive MalignanciesNot yet recruitingNCT07014254Not applicable
- Life Following Excision of Neuroendocrine TumorsRecruitingNCT06981455
- Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsRecruitingNCT06943755Phase 2/3
- A Study of MT-4561 in Patients With Various Advanced Solid TumorsRecruitingNCT06943521Phase 1/2
- 18F Labeled FAP Targeted Molecular Probe in Early Tumor DiagnosisRecruitingNCT06937112
- Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)RecruitingNCT06926634Phase 2
- Fecal Microbiota Transplantation for Preventing Gastrointestinal Symptoms in Extrapulmonary Neuroendocrine Neoplasms: A Real-World StudyNot yet recruitingNCT06924645Not applicable
- Addressing Social Determinants of Health Among Metro Detroit Cancer SurvivorsRecruitingNCT06908629Not applicable
- Endoscopic Resection for Small Rectal Neuroendocrine TumorsNot yet recruitingNCT06901856Not applicable
- SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)RecruitingNCT06889493Phase 1
- A Phase 3 Study of Ersodetug in Patients With Tumor HyperinsulinismRecruitingNCT06881992Phase 3
- Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine TumorsRecruitingNCT06878664Phase 3
- Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA TrialRecruitingNCT06855095Phase 2/3
- High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection MarginsRecruitingNCT06835426Not applicable
- A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-KitRecruitingNCT06805825Phase 1
- Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative DiseasesRecruitingNCT06788886Not applicable
- EpigenOMic Determinants of the Neuroendocrine Phenotype As Biomarkers for Neuroendocrine NeoplasmsRecruitingNCT06785597
- Use of 68Ga-DOTATOC PET/CT-enterography for Detection of the Primary Lesion in Neuroendocrine Tumors of the Small BowelRecruitingNCT06773624Not applicable
- Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine TumorsNot yet recruitingNCT06764368Phase 2
- Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NENRecruitingNCT06735560Not applicable
- A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-NensRecruitingNCT06732505Phase 1
- Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine TumorsRecruitingNCT06679816Phase 4
- Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).RecruitingNCT06607692Phase 1/2
- Clinical-pathological Evaluation of Pit-NETsNot yet recruitingNCT06607198
- A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNETRecruitingNCT06592989
- Collection of Liquid Biopsy Samples of Neuroendocrine Neoplasms (NEN) Patients - Collection of NET (CollectNET) 2.0, a Study by the BE-FORCE ConsortiumRecruitingNCT06541080
- Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine TumorRecruitingNCT06540937Phase 2
- Genetic Bases of Neuroendocrine Neoplasms in Mexican PatientsRecruitingNCT06523582
- Generation of Organoids of Neuroendocrine Neoplasms of the Gastro-Entero-Pancreatic Tract Obtained From Patients Undergoing SurgeryRecruitingNCT06519500
- A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid TumorsRecruitingNCT06505824Phase 1
- Irinotecan Liposomes for the Treatment of Neuroendocrine CarcinomaNot yet recruitingNCT06485739Phase 4
- Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine TumorsRecruitingNCT06472388Phase 2
- 61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET)RecruitingNCT06455358Phase 1/2
- Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive TumorsRecruitingNCT06441331Phase 1
- Study of the Value of hPG80 (Circulating Progastrin) for the Diagnosis of Neuroendocrine Tumours in Patients With an MEN1 MutationRecruitingNCT06430021
- A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and ToxicityRecruitingNCT06406465Phase 2
- Observational Study on GEP-and Pulm-NET Treated at FPGRecruitingNCT06402695
- 177Lu-DOTATATE Modified Delivery Based on Individualized DosimetryRecruitingNCT06395402Phase 2
- Influence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated GEP-NENsRecruitingNCT06356467
- Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine TumoursRecruitingNCT06345079Phase 2
- SSTR PET/CT for Preoperative N Stage Evaluation in GEP-NETsNot yet recruitingNCT06344832
- Iconographic Registry of Pancreatobiliary Endoscopy ProceduresRecruitingNCT06344507
- Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 PatientsRecruitingNCT06343428
- YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs.RecruitingNCT06337760
- Early Identification of Cardiac Involvement in Patients With Carcinoid: Clinical and Prognostic ImplicationsRecruitingNCT06321692Not applicable
- A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine TumorsNot yet recruitingNCT06300216
- Lateral Pelvic Lymph Node Dissection for Rectal Neuroendocrine Neoplasms Undergoing Laparoscopic Total Mesenteric ExcisionRecruitingNCT06279299Not applicable
- Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine TumorsRecruitingNCT06276309
- EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.RecruitingNCT06263088Not applicable
- In Vitro Organoid Drug Sensitivity-Guided Treatment for Advanced Pancreatic Neuroendocrine TumorRecruitingNCT06246630Not applicable
- Clinical Application of the J-PET Scanner PrototypeRecruitingNCT06242119
- Comparison of Kimura Versus Warshaw Technique for Laparoscopic Spleen-Preserving Distal PancreatectomyNot yet recruitingNCT06167421Not applicable
- Evaluation of the Diagnostic and Prognostic Role of PET (PET/CT and PET/MRI) in Neuroendocrin Tumors.RecruitingNCT06159920
- 68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine TumoursRecruitingNCT06155318
- Device Assisted Full Thickness Resection Versus Endoscopic Submucosal Dissection for Duodenal Neuroendocrine TumorsRecruitingNCT06121752Not applicable
- Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed IndicationsNot yet recruitingNCT06121271Phase 2
- Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine TumorsRecruitingNCT06056362Phase 1/2
- "Receptor Radionuclide Therapy With 177Lu-DOTATOCRecruitingNCT06045260Phase 2
- Evaluation of the Quality of Life and Tolerance of Patients Treated With Vectorized Internal Radiotherapy (RIV) for a Neuro Endocrine Tumor (NET) in the Auvergne-Rhône-Alpes Region.RecruitingNCT06043193
- A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath TumorsRecruitingNCT06041516Phase 1
- Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other ExaminationsRecruitingNCT06041009
- An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine TumorsRecruitingNCT06038461Phase 1/2
- Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine TumorsRecruitingNCT06015802
- Surufatinib in G3 Neuroendocrine TumorsNot yet recruitingNCT05973968
- Evaluation of Study Experiences of Neuroendocrine Tumor PatientsNot yet recruitingNCT05967481
- Value of Right-sided Hemicolectomy for Chldren With High-risk Neuroendocrine Tumors of the AppendixRecruitingNCT05919758
- Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.RecruitingNCT05918302Phase 3
- Long-term Prognosis for Non-functional Neuroendocrine Tumors of the Pancreatic Body and Tail ≤ 3cmRecruitingNCT05907824
- Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine TumorsNot yet recruitingNCT05894486Phase 2
- Improving Peptide Receptor Radionuclide Therapy With PARP InhibitorsRecruitingNCT05870423Phase 1
- The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection StudyRecruitingNCT05804331
- Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine TumorsRecruitingNCT05746208Phase 2
- Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine NeoplasmsEnrolling by invitationNCT05709171Phase 2
- Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtientsRecruitingNCT05701241Phase 4
- 68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine TumorsRecruitingNCT05673031